Top Page
Alligator Bioscience AB
(ATORX)
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Alligator Bioscience AB Business Overview & Revenue Model
Alligator Bioscience AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.51M | 57.77M | 58.11M | 35.70M | 12.94M | 4.35M |
| Gross Profit | 20.92M | 57.77M | 58.11M | -112.03M | -74.04M | -77.97M |
| EBITDA | -794.00K | -165.47M | -237.61M | -180.99M | -130.39M | -131.46M |
| Net Income | -77.72M | -233.89M | -248.59M | -193.40M | -141.74M | -143.61M |
Balance Sheet | ||||||
| Total Assets | 76.76M | 104.34M | 118.45M | 169.58M | 333.20M | 151.94M |
| Cash, Cash Equivalents and Short-Term Investments | 25.07M | 64.31M | 66.12M | 97.31M | 278.15M | 103.34M |
| Total Debt | 37.19M | 43.57M | 16.10M | 24.50M | 9.74M | 12.07M |
| Total Liabilities | 86.01M | 234.93M | 106.59M | 80.53M | 50.93M | 36.69M |
| Stockholders Equity | -9.25M | -130.59M | 11.86M | 89.05M | 282.27M | 115.24M |
Cash Flow | ||||||
| Free Cash Flow | -165.18M | -212.43M | -191.74M | -173.05M | -127.08M | -141.45M |
| Operating Cash Flow | -163.72M | -212.43M | -189.28M | -172.61M | -127.03M | -141.35M |
| Investing Cash Flow | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K | 156.89M |
| Financing Cash Flow | 140.23M | 211.27M | 161.56M | -7.83M | 301.80M | -6.15M |
Alligator Bioscience AB Technical Analysis
Alligator Bioscience AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr144.81M | -2.95 | -52.45% | ― | 2.56% | 52.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr36.14M | -0.72 | -294.38% | ― | 186.74% | 73.17% | |
43 Neutral | kr37.70M | -1.37 | -166.94% | ― | ― | -19.35% | |
42 Neutral | kr81.37M | -2.71 | -20.85% | ― | -67.00% | 13.62% | |
41 Neutral | kr93.50M | -0.09 | ― | ― | 52.38% | 74.36% | |
41 Neutral | kr109.66M | -1.29 | -1291.15% | ― | ― | 28.54% |
Alligator Bioscience AB Corporate Events
Alligator Bioscience will present new clinical data from its Phase 1b/2 OPTIMIZE-1 study of the CD40 agonist mitazalimab in combination with standard mFOLFIRINOX chemotherapy in previously untreated metastatic pancreatic ductal adenocarcinoma at the ASCO Gastrointestinal Cancers Symposium 2026 in San Francisco. The final efficacy analyses further characterize the clinical benefit of the combination and support Alligator’s preparations for pivotal development of mitazalimab, potentially strengthening the drug’s profile in a highly challenging cancer indication and reinforcing the company’s positioning in CD40-based immunotherapy as it engages key opinion leaders and advances toward Phase 3.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience’s board has executed a directed issue of 18,585,000 units to guarantors of its recent rights issue, with each unit consisting of two ordinary shares and one warrant, at a subscription price of SEK 0.40 per unit (SEK 0.20 per share), matching the rights issue terms. Eleven guarantors opted to take their guarantee compensation in newly issued units worth approximately SEK 7.4 million, while the remaining guarantors will receive around SEK 3.8 million in cash, and the board has also approved a directed issue of 28,132,473 warrants to Fenja Capital, collectively strengthening the company’s capital structure and aligning key investors through equity-linked instruments, albeit at the cost of further dilution for existing shareholders.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience has completed a rights issue of units that was subscribed to about 64.8 percent, with approximately 61.2 percent taken up by existing shareholders through unit rights and 3.6 percent subscribed without rights, while guarantee commitments will cover around 9.1 percent of the issue. The transaction will initially raise roughly SEK 91 million before costs and loan repayments, significantly increasing the company’s share count and resulting in an estimated 91.2 percent dilution for existing shareholders, with the potential for a further dilution of about 31.3 percent if all associated TO 14 warrants are exercised in March 2026, which could bring in up to SEK 57 million more and materially extend the company’s funding but at a substantial ownership dilution.
Alligator Bioscience has reported the preliminary outcome of its recently completed rights issue of units, indicating a subscription level of approximately 64.8 percent, of which 61.2 percent came through the exercise of unit rights and 3.6 percent without rights. As a result, guarantee commitments will be utilized for about 9.1 percent of the offering, and the company expects to raise roughly SEK 91 million before issue costs and debt repayments, including bridge loans and part of an outstanding loan to Fenja Capital II A/S. The rights issue, which comprised up to 306.7 million units—each consisting of two ordinary shares and one warrant—closed on 18 December 2025, with the final outcome scheduled to be announced on 22 December 2025, providing Alligator with important capital to support its ongoing operations and clinical pipeline.
Alligator Bioscience has commented on Shanghai Henlius Biotech’s recent regulatory approval in China to begin Phase 2/3 trials of HLX22, a monoclonal antibody for treating HER2-positive breast cancer. Although Alligator is not directly involved in the development, the company stands to benefit financially from potential future revenues due to its licensing agreement with AbClon, which entitles Alligator to a share of Henlius’ revenues from HLX22.
Alligator Bioscience AB has published a supplement prospectus related to its rights issue, which includes ordinary shares and warrants, approved by the Swedish Financial Supervisory Authority. The rights issue subscription period runs from December 4 to December 18, 2025, with trading in unit rights available until December 15, 2025. This move is part of the company’s strategy to secure additional subscription undertakings and guarantee commitments, potentially strengthening its financial position and supporting its ongoing drug development efforts.
Alligator Bioscience has released its financial calendar for 2026, detailing key dates for shareholders and stakeholders, including the submission deadline for resolutions, various interim and annual reports, and the Annual General Meeting. This announcement provides stakeholders with a clear timeline for the company’s financial disclosures and meetings, which is crucial for maintaining transparency and engagement with investors.
Alligator Bioscience AB has announced additional subscription undertakings and guarantee commitments for its upcoming rights issue, increasing the total commitments from approximately SEK 78 million to SEK 91 million. This financial support from both existing and new investors, including Roxette Photo SA, Magnus Petersson, and HDF Impact BV, strengthens the company’s ability to advance its mitazalimab treatment towards the market, highlighting investor confidence in Alligator Bioscience’s strategic direction.
Alligator Bioscience announced the publication of Phase 1 trial data for mitazalimab in Nature Communications, showcasing its potential in treating metastatic pancreatic ductal adenocarcinoma. The study demonstrated significant immunological effects, including reduced tumor fibrosis and increased T-cell infiltration, supporting mitazalimab’s role in reshaping the tumor microenvironment. These findings reinforce the drug’s potential in combination therapies for hard-to-treat cancers, aligning with Alligator’s broader clinical strategy.
Alligator Bioscience AB has announced a rights issue to raise approximately SEK 123 million, with the potential for an additional SEK 61 million through warrants. The funds will be used to repay loans and support the ongoing process to secure a partnership for mitazalimab, as well as for general corporate purposes. The rights issue is partially covered by subscription undertakings and guarantee commitments, ensuring a significant portion of the funds is secured.
Alligator Bioscience AB held an extraordinary general meeting on November 25, 2025, where several key resolutions were adopted. The company decided to amend its Articles of Association to adjust the limits for share capital and the number of shares, and to decrease its share capital to cover losses. Additionally, the meeting approved a rights issue of units, which is expected to raise approximately SEK 123 million before costs, and authorized the board to issue shares and warrants to guarantors and Fenja Capital II A/S as part of a loan restructuring. These measures aim to strengthen the company’s financial position and support its ongoing development efforts.
Alligator Bioscience AB has announced the final terms of its Rights Issue, which involves issuing units of ordinary shares and warrants to existing shareholders. The initiative aims to raise approximately SEK 123 million initially, with potential additional proceeds of SEK 61 million if warrants are fully exercised. The funds will be used to repay loans and support the company’s ongoing efforts to secure a partnership for its cancer treatment, mitazalimab, as well as for general corporate purposes. The Rights Issue is partially covered by subscription undertakings and guarantee commitments, ensuring a significant portion of the funds is secured.
Alligator Bioscience announced new data on its immuno-oncology drugs, mitazalimab and ATOR-4066, at the SITC 40th Anniversary Annual Meeting. The data on mitazalimab, from the OPTIMIZE-1 trial in metastatic pancreatic cancer, supports the selection of a 900 μg/kg dose for a planned Phase 3 study, showing improved survival outcomes and manageable safety. Preclinical findings on ATOR-4066 demonstrate its potential in immune activation and tumor microenvironment remodeling, highlighting its superior efficacy compared to CD40 monospecific antibodies.
Alligator Bioscience has announced the appointment of its Nomination Committee in preparation for the Annual General Meeting (AGM) scheduled for May 6, 2026. The committee, comprising representatives from the company’s largest shareholders and the Chairman of the Board, is tasked with preparing proposals for the AGM, including board member nominations and remuneration. This strategic move is crucial for aligning shareholder interests and ensuring effective governance, potentially impacting the company’s operational and strategic direction.
Alligator Bioscience AB reported significant progress in its clinical and financial endeavors for the period ending September 2025. The company achieved a major milestone with the successful execution of its TO 13 warrant program, raising SEK 28.1 million, and announced promising 30-month survival results for mitazalimab, reinforcing its potential as a transformative treatment for pancreatic cancer. Additionally, Alligator expanded its mitazalimab development through a Phase 2/3 trial for biliary tract cancer and advanced its HLX22 program for HER2-positive gastric cancer. The company also secured a strategic partnership for its RUBY™ bispecific antibody format, showcasing its versatility beyond oncology. Looking ahead, Alligator plans a rights issue to support its financial runway and Phase 3 preparations for mitazalimab.
Alligator Bioscience AB has announced an extraordinary general meeting to discuss significant resolutions, including amendments to the Articles of Association and a decrease in share capital to cover losses. These proposed changes reflect the company’s strategic efforts to strengthen its financial position and operational framework, potentially impacting its market standing and stakeholder interests.
Alligator Bioscience AB has announced a rights issue of units worth approximately SEK 120 million, subject to approval at an extraordinary general meeting. The funds raised will be used to repay loans and support ongoing projects, including securing a partnership for mitazalimab. The rights issue is partially covered by subscription undertakings and guarantee commitments, and the company has also secured bridge loans to meet liquidity needs until the rights issue is completed.
Alligator Bioscience has been granted a US patent for its bispecific antibody, ATOR-4066, which targets CD40 and CEACAM5. This patent, effective until 2043, strengthens the company’s intellectual property and supports its pipeline of innovative immunotherapies. The patent underscores the company’s commitment to advancing novel cancer treatments and reinforces its position in the immuno-oncology field.
Alligator Bioscience has announced an upcoming earnings call on October 23, 2025, to discuss its third-quarter interim report. The call, led by CEO Søren Bregenholt and CFO Johan Giléus, will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.